Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The abscopal effect is a phenomenon in which local radiotherapy is associated with the regression of metastatic cancer at a distance from the irradiated site. The abscopal effect may be mediated by activation of the immune system. Ipilimumab is a monoclonal antibody that inhibits an immunologic checkpoint on T cells, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). We report a case of the abscopal effect in a patient with melanoma treated with ipilimumab and radiotherapy. Temporal associations were noted: tumor shrinkage with antibody responses to the cancer-testis antigen NY-ESO-1, changes in peripheral-blood immune cells, and increases in antibody responses to other antigens after radiotherapy. (Funded by the National Institutes of Health and others.).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345206 | PMC |
| http://dx.doi.org/10.1056/NEJMoa1112824 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: Abscopal effect and long-term survival in a PD-L1 negative NSCLC patient treated with radiotherapy and immuno-chemotherapy.
Front Immunol
September 2025
Department of Radiation Oncology, Jiangxi Cancer Hospital and Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
We present a case of a 68-year-old male with advanced non-small cell lung cancer (NSCLC), PD-L1 negative and driver gene negative, who exhibited a significant abscopal effect following radiotherapy combined with systemic immunotherapy (sintilizumab) and chemotherapy. The patient achieved complete remission (CR) of intracranial metastases without cranial irradiation, suggesting a systemic immune response triggered by the combination of radiotherapy and immunotherapy. This case highlights the potential of radiotherapy combined with immuno-chemotherapy to induce abscopal effects, even in PD-L1 negative patients, and underscores the importance of further investigation into this therapeutic strategy.
View Article and Find Full Text PDFA non-small cell lung cancer fragile elderly patient treated with immunotherapy and non-ablative radiation therapy: a case report of a winning combination.
Front Oncol
August 2025
Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, Pavia, Italy.
Background: Radiation therapy is used in the clinical scenario of oligo-metastatic lung cancer as a weapon to delay the subsequent line of systemic therapy, particularly in the case of oligo-progressive disease. In this setting, the integration of immunotherapy and radiotherapy plays an important role to achieve local control and improve progression-free survival (PFS).
Case Presentation: We reported the case of an elderly fragile patient affected by advanced non-small cell lung cancer treated with pembrolizumab as first systemic line and immuno-modulant radiation therapy at oligo-progression.
Nanofilament immunotherapy induces potent antitumor vaccine responses.
J Immunother Cancer
August 2025
TATUM bioscience, Sherbrooke, Quebec, Canada.
Background: Checkpoint inhibitors revolutionized cancer treatment by potentiating antitumor immune responses. However, many patients do not respond to these therapies, often due to the lack of a pre-existing immune response against cancer cells. Developing immunotherapies that promote cancer-cell antigen recognition, and the initiation of antitumor immune responses could thus improve response rates.
View Article and Find Full Text PDFCase Report: Complete response with combination oncolytic virus immunotherapy in a patient with stage IV renal cell carcinoma-a promising innovative approach.
Front Oncol
August 2025
Research and Development, RapoYerape Ltd., Jerusalem, Israel.
Metastatic renal cell carcinoma stage IV (RCC-IV) remains a therapeutic challenge, with an overall 5-year survival rate of 12%. Conventional chemotherapy and radiotherapy have shown relatively low efficacy in reducing morbidity and mortality, whereas innovative immunotherapies have demonstrated promising clinical results with fewer adverse events (AEs). Oncolytic virus (OV) immunotherapy has produced remarkable therapeutic effects in many solid tumors, including refractory and end-stage tumors, with intratumoral (IT) injection (IT-OV) suggested to enhance both efficacy and tolerability.
View Article and Find Full Text PDFIn Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation.
Adv Sci (Weinh)
August 2025
South Australian ImmunoGENomics Cancer Institute, The University of Adelaide, Adelaide, SA, 5005, Australia.
Historically, directly injecting therapeutics into tumors has been deemed suboptimal and less favorable in clinical settings compared to systemic administration due to the inability to eradicate circulating/metastatic tumor cells until the emergence of the concept of in situ vaccine. In situ vaccine leverages patients' own tumors as a pool of antigens to elicit systemic antitumor immunity (also known as "abscopal effect") that aims to eliminate both primary and distal/metastatic tumors. One typical example of an approved product is Talimogene laherparepvec, an oncolytic virus approved in 2015 for treating advanced melanoma.
View Article and Find Full Text PDF